This activity is designed to inform physicians about the latest treatment advances and data in the management of triple-negative breast cancer (TNBC), including approved and investigational treatment strategies.
Instructions For This Activity & Receiving Credit
This activity is directed toward medical oncologists, nurses, and nurse practitioners who manage and treat patients with TNBC. Breast surgeons, surgical oncologists, radiation oncologists, pathologists, fellows, physician assistants, and other healthcare providers interested in the treatment of TNBC are also invited to participate.
Kelly McCoy Hayden, PhD
Disclosure: No relevant financial relationships with commercial interests to disclose.
Debu Tripathy, MD
Professor and Chair
Department of Breast Medical Oncology
The University of Texas MD Anderson Cancer Center
Disclosure: Grant/research support from Genentech/Roche, Pfizer, Puma Inc, and Novartis (clinical trial support contracted to the University of Southern California and MD Anderson Cancer Center); consultant for Eisai, Oncoplex Diagnostics, Merck, and Novartis.
Tiffany A. Traina, MD
Assistant Attending Physician
Breast Medicine Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
Assistant Professor of Medicine
Weill Cornell Medical College
New York, NY
Disclosure: Consultant: Genentech/Roche, Eisai, Halozyme, Mundipharma, Medivation, Pfizer, AstraZeneca, Bayer, and Immunomedics; grant/research support: Medivation, Eisai, Pfizer, Novartis, and Myriad Genetics.
The staff of Physicians' Education Resource®, LLC, (PER®) and the editorial staff of The American Journal of Hematology/Oncology® have no relevant financial relationships with commercial interests to disclose.
In accordance with Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial SupportSM, PER® resolved all conflicts of interest prior to the release of this CME activity using a multistep process.
Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is funded by Physicians' Education Resource®, LLC.
This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for CME purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient's medical condition.